© PEPR MED-OOC

Organs and organoids chips (MED-OOC) PEPR

Revolutionising medicine with organs- and organoids-on-chips

Faced with the limitations of the models currently used for clinical trials, the MED-OOC research programme aims to develop a new generation of miniaturized biological models based on human cells. These devices, which combine cell engineering, microfluidics and cutting-edge technologies, promise to faithfully reproduce the functions of human organs and finely model human pathologies, paving the way for more personalized, effective and ethical medicine.

  • Exploration national research programme
  • Programme leaders: CEA, CNRS, Inserm
  • Programme directors:
    • Anne-Marie Gué - CNRS (Laboratoire d'analyse et d'architecture des systèmes (LAAS-CNRS))
    • Xavier Gidrol - CEA
    • Maxime Mahé - Inserm
  • Budget: €48,4m
  • Duration: 6 years (2024 to 2030)

The development of organs- and organoids-on-chip is based on advances in cell biology, microtechnology and imaging. Their aim is to recreate a controlled microenvironment capable of simulating the real physiological dynamics of an organ, or even several interconnected organs. Three major scientific challenges are addressed: integrating sensors for real-time monitoring, customizing chips using patients’ cells, and developing multi-organ, multi-function approaches.

The applications cover a wide spectrum: therapeutic decision support for cancers, monitoring of pancreatic transplants in type 1 diabetes, and the study of metabolic imbalances linked to chronic diseases. The organ-on-chip technology is also a powerful tool for developing and testing new therapies.

By helping to reduce animal testing, personalize care and strengthen the competitiveness of the biomedical field, MED-OOC is fully in line with the challenges of public health, therapeutic innovation and scientific sovereignty.

PEPR MED-OOC website

PEPR MED-OOC LinkedIn page

MED-OOC